Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation

International Journal of Hematology

Volumn 91, Issue 5, 2010, Pages 776-783

  Ieko, Masahiro ^a   Yoshida, Mika ^a   Naito, Sumiyoshi ^a   Nakabayashi, Toru ^a   Kanazawa, Kaoru ^a   Mizukami, Kazuhiro ^a   Mukai, Masaya ^b   Atsumi, Tatsuya ^c   Koike, Takao ^c  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^b SAPPORO CITY GENERAL HOSPITAL   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiphospholipid syndrome; Systemic lupus erythematosus; Thrombin activatable fibrinolysis inhibitor; Thrombosis

Indexed keywords

ANTIGEN; IMMUNOGLOBULIN G; PHOSPHOLIPID ANTIBODY; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR ANTIGEN; THROMBOMODULIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR; THROMBOSIS;

ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CARBOXYPEPTIDASE U; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RISK FACTORS; THROMBOSIS; CARBOXYPEPTIDASE B2;

EID: 77954540087     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0590-0     Document Type: Article

References (53)

1. GRV Hughes 1993 The antiphospholipid syndrome: ten years on Lancet 342 341 344 10.1016/0140-6736(93)91477-4 8101587 1:STN:280:DyaK3szivF2gug%3D%3D (Pubitemid 23227565)
2. S Miyakis MD Lockshin T Atsumi DW Branch RL Brey R Cervera, et al. 2006 International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost 4 295 306 10.1111/j.1538-7836.2006.01753.x 16420554 1:CAS:528:DC%2BD28XisVSjuro%3D
3. T Atsumi M Ieko ML Bertolaccini K Ichikawa A Tsutsumi E Matsuura, et al. 2000 Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant Arthritis Rheum 43 1982 1993 10.1002/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2 11014348 1:CAS:528:DC%2BD3cXnt1Kns7g%3D
4. T Atsumi MA Khamashita C Andujar MJ Leandro O Amengual PRJ Ames, et al. 1998 Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome J Rheumatol 25 69 73 9458205 1:STN:280:DyaK1c7hslCjuw%3D%3D
5. M Cugno M Cabibbe M Galli PL Meroni S Caccia R Russo, et al. 2004 Antibodies to tissue-plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients Blood 103 2121 2126 10.1182/blood-2003-07-2422 14630788 1:CAS:528:DC%2BD2cXitlequro%3D (Pubitemid 38326228)
6. L Bajzar R Manuel ME Nesheim 1995 Purification characterization of TAFI a thrombin-activable fibrinolysis inhibitor J Biol Chem 270 14477 14484 10.1074/jbc.270.24.14477 7782309 1:CAS:528:DyaK2MXmsVSit7g%3D
7. D Hendriks S Scharpe M van Sande MP Lommaert 1989 A labile enzyme in fresh human serum interferes with the assay of carboxypeptidase N Clin Chem 35 177 2910562 1:STN:280:DyaL1M%2FptVWguw%3D%3D
8. W Campbell H Okada 1989 An arginin specific carboxypeptidase generated in blood during coagulation of inflammation which is unrelated to carboxypeptidase N Biochem Biophys Res Commun 162 933 939 10.1016/0006-291X(89)90762-6 2504159 1:CAS:528:DyaL1MXlt12kurk%3D (Pubitemid 19214673)
9. DL Eaton BE Malloy SP Tsai W Henzel D Drayna 1991 Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma J Biol Chem 266 21833 21838 1939207 1:CAS:528:DyaK38Xlt1OhsLY%3D
10. T Kawanura N Okada H Okada 2002 Elastase from activated human neutrophils activates procarboxypeptidase R Microbiol Immunol 46 225 230
11. HC Cote L Bajzar WK Stevens JA Samis J Morser RT MacGillivray, et al. 1997 Functional characterization of recombinant human meizothrombin and meizothrombin (desF1). Thrombomodulin-dependent activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI), platelet aggregation, antithrombin-III inhibition J Biol Chem 272 6194 6200 10.1074/jbc.272.38.23792 9045633 1:CAS:528:DyaK2sXhvVOqs7w%3D (Pubitemid 27410957)
12. MB Boffa W Wang L Bajzar ME Nesheim 1998 Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activate TAFI compared with respect to glycation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties J Biol Chem 273 2127 2135 10.1074/jbc.273.4.2127 9442053 1:CAS:528:DyaK1cXnsVKgtA%3D%3D (Pubitemid 28069262)
13. W Wang MB Boffa L Bajzar JB Walker ME Nesheim 1998 A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor J Biol Chem 273 27176 27181 10.1074/jbc.273.42.27176 9765237 1:CAS:528:DyaK1cXntVSht7g%3D (Pubitemid 28500426)
14. M Schneider M Nesheim 2004 A study of protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis J Biol Chem 279 13333 13339 10.1074/jbc.M313164200 14715655 1:CAS:528:DC%2BD2cXis1emtb4%3D (Pubitemid 38468855)
15. M Schneider N Brufatto E Neill M Nesheim 2004 Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high-molecular weight fibrin degradation products to protect plasmin from antiplasmin J Biol Chem 279 13340 13345 10.1074/jbc.M313211200 14715654 1:CAS:528:DC%2BD2cXis1emtb8%3D (Pubitemid 38468856)
16. J Leurs V Nerme Y Sim D Hendriks 2004 Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism J Throm Haemost 2 416 423 10.1111/j.1538-7836.2004.00605.x 1:CAS:528:DC%2BD2cXktVGms7w%3D (Pubitemid 40185652)
17. J Walker L Bajzar 2004 The intrinsic threshold of the fibrinolysis system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activatable fibrinolysis inhibitor is masked by its instability J Biol Chem 279 27896 27904 10.1074/jbc.M401027200 15128744 1:CAS:528:DC%2BD2cXlt1Clsb0%3D (Pubitemid 38900058)
18. NH van Tilburg FR Rosendaal RM Bertina 2000 Thrombin activatable fibrinolysis inhibitor and risk for deep vein thrombosis Blood 95 2855 2859 10779431
19. S Eichinger V Schönauer A Waltermann E Minar C Biolonczyk M Hirschl, et al. 2004 Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism Blood 103 3773 3776 10.1182/blood-2003-10-3422 14739223 1:CAS:528:DC%2BD2cXjvF2iuro%3D (Pubitemid 38596294)
20. EJ Libourel I Bank JR Meinardi CP Balje-Volkers K Hamulyak S Middeldorp, et al. 2002 Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism Haematologica 87 1068 1073 12368162 1:CAS:528: DC%2BD38XovFKrsrk%3D
21. ME Meltzer CJM Doggen PG de Groot JCM Meijers FR Rosendaal T Lisman 2009 Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men Haematologica 94 811 818 10.3324/haematol.2008.002386 19377074 1:CAS:528:DC%2BD1MXovFeisro%3D
22. A Santamaria A Martniez-Rubio M Borrell J Matero R Ortin J Fontcuberta 2004 Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level Haematologica 89 880 881 15257950 1:CAS:528:DC%2BD2cXnsFSmtrg%3D
23. V Schroeder M Wilmer B Buehler HP Kohler 2006 TAFI activity in coronary artery disease: a contribution to the current discussion on TAFI assays Thromb Haemost 96 236 237 16894472 1:CAS:528:DC%2BD28Xpt1ShsLY%3D
24. I Juhan-Vague PE Morange H Aubert M Henry MF Aillaud MC Alessi, et al. 2002 Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe Arterioscler Thromb Vasc Biol 22 867 873 10.1161/01.ATV.0000015445.22243. F4 12006404 1:CAS:528:DC%2BD38XjslGmu74%3D (Pubitemid 34517803)
25. E Zorio R Castello C Falco F Espana A Osa L Almenar, et al. 2003 Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system Br J Haematol 122 958 965 10.1046/j.1365-2141.2003.04549.x 12956767 1:CAS:528:DC%2BD3sXotFKns7w%3D (Pubitemid 37174617)
26. R Brouns E Heylen JL Willemse R Sheorajpanday D de Surgeloose R Verkerk, et al. 2010 The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlated with stroke severity, evolution and outcome J Thromb Haemost 8 75 80 10.1111/j.1538-7836.2009.03663.x 19874466 1:CAS:528: DC%2BC3cXhsFCltrc%3D
27. M Henry H Aubert PE Morange I Nanni MC Alessi L Tiret, et al. 2001 Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled Blood 97 2053 2058 10.1182/blood.V97.7.2053 11264171 1:CAS:528:DC%2BD3MXjvFCqs78%3D (Pubitemid 32239086)
28. H Akatsu M Ishiguro N Ogawa T Kanesaki N Okada T Yamamoto, et al. 2007 Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal Japanese population Microbiol Immunol 51 507 517 17579260 1:CAS:528:DC%2BD2sXntV2ltrw%3D
29. WA Wilson AE Gharavi T Koike MD Lockshin DW Branch JC Piette, et al. 1999 International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop Arthritis Rheum 42 1309 1311 10.1002/1529-0131(199907)42:7<1309::AID- ANR1>3.0.CO;2-F 10403256 1:STN:280:DyaK1MzjtVSmsg%3D%3D (Pubitemid 30265586)
30. EN Harris AE Gharavi SP Patel GR Hughes 1987 Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986 Clin Exp Immunol 68 215 222 3652514 1:STN:280:DyaL1c%2Fgt12ltQ%3D%3D
31. JT Brandt DA Triplett B Alving I Scharrer 1995 Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH Thromb Haemost 74 1185 1190 8560433 1:CAS:528: DyaK2MXptVyhs7Y%3D
32. J Leuis D Hendriks 2005 Carbpxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease Thromb Haemost 94 471 487
33. K Ichikawa MA Khamashta T Koike E Matsuura GR Hughes 1994 β2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome Arthritis Rheum 37 1453 1461 10.1002/art.1780371008 7945470 1:STN:280:DyaK2M%2Fjt1aitA%3D%3D (Pubitemid 24337688)
34. M Ieko K Ichikawa DA Triplett E Matsuura T Atsumi K Sawada, et al. 1999 β2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies Arthritis Rheum 42 167 174 10.1002/1529-0131(199901) 42:1<167::AID-ANR20>3.0.CO;2-B 9920027 1:CAS:528:DyaK1MXosF2itQ%3D%3D (Pubitemid 29042583)
35. ME Viveros J Cabiedes E Reyes AR Cabral 2005 Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-β2-glycoprotein-I antibodies Rev Invest Clin 57 563 571 16315641 1:CAS:528:DC%2BD2MXht1Kqsr3P
36. J Nojima H Kuratsune E Suehisa Y Iwatani Y Kanakura 2005 Acquired activated protein C resistance associated with IgG antibodies against β2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism Clin Chem 51 545 552 10.1373/clinchem.2004.043414 15637132 1:CAS:528:DC%2BD2MXitVOgtrg%3D (Pubitemid 40300230)
37. M Ymazaki H Asakura H Jokaji M Saito C Uotani I Kumabashiri, et al. 1994 Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome Thromb Haemost 71 424 427
38. R Takeuchi T Atsumi M Ieko Y Amasaki K Ichikawa T Koike 2002 Suppressed intrinsic fibrinolytic activity by monoclonal anti-β2 glycoprotein I antibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome Br J Haematol 119 781 788 10.1046/j.1365-2141.2002.03928.x 12437660 1:CAS:528:DC%2BD3sXpsFGq (Pubitemid 35366224)
39. S Yasuda M Bohgaki T Atsumi T Koike 2005 Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway Immunobiology 210 775 780 10.1016/j.imbio.2005.10.009 16325497 1:CAS:528:DC%2BD28XosFeqtA%3D%3D (Pubitemid 41683862)
40. T Atsumi MA Khamashta O Amengual GRV Hughes 1997 Up-regulated tissue factor expression in antiphospholipid syndrome Thromb Haemost 77 222 223 9031483 1:CAS:528:DyaK2sXhtFSkurk%3D
41. C Lopez-Pedrera P Buendia MJ Cuadrado E Siendones MA Aguirre N Barbarroja, et al. 2006 Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-κB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway Arthritis Rheum 54 301 311 10.1002/art.21549 16385547 1:CAS:528:DC%2BD28XhsVensbo%3D (Pubitemid 43122214)
42. A Donmez K Aksu HA Celik G Keser S Cagirgan SB Omay, et al. 2005 Thrombin activatable fibrinolysis inhibitor in Behcet's disease Thromb Res 115 287 292 10.1016/j.thromres.2004.09.010 15668188 1:CAS:528:DC%2BD2MXmvFKhtQ%3D%3D
43. T Sato T Miwa H Akatsu N Matsukawa K Obata N Okada, et al. 2000 Procarboxypeptidase R is an acute phase protein in mouse, whereas carboxypeptidase N is not J Immunol 165 1053 1058 10878383 1:CAS:528: DC%2BD3cXkvFWit7g%3D
44. MB Boffa JD Hamill D Maret D Brown ML Scott ME Nesheim, et al. 2003 Acute phase mediators modulate thrombin-activatable fibrinolysis inhibitor (TAFI) gene expression in Hep 2 cells J Biol Chem 278 9250 9257 10.1074/jbc.M209588200 12645517 1:CAS:528:DC%2BD3sXhvV2jtrs%3D (Pubitemid 36800408)
45. T Myles T Nishimura TH Yun M Nagashima J Morser AJ Patterson, et al. 2003 Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation J Biol Chem 278 51059 51067 10.1074/jbc.M306977200 14525995 1:CAS:528:DC%2BD3sXpslOhs7c%3D (Pubitemid 38020340)
46. D Maret MB Boffa DF Brain ME Nesheim ML Koschinsky 2004 Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor J Thromb Heamost 2 1969 1979 10.1111/j.1538-7836.2004.00971.x 1:CAS:528:DC%2BD2cXhtFagsL3M (Pubitemid 40192751)
47. PL Meroni E Raschi C Testoni A Tincani G Balestrieri R Molteni, et al. 2001 Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2-glycoprotein I) antibodies Arthritis Rheum 44 2870 2878 10.1002/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y 11762948 1:CAS:528:DC%2BD38XislCltQ%3D%3D (Pubitemid 34016207)
48. RR Forastero ME Martinuzzo GE de Larranaga 2005 Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies Lupus 14 129 136 10.1191/0961203305lu2048oa (Pubitemid 40327663)
49. PG de Groot DA Horbach RH Derksen 1996 Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis Lupus 5 488 493 8902788
50. DM Keeling AJ Wilson IJ Mackie DA Isenberg SJ Machin 1993 Role of β2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro J Clin Pathol 46 908 911 10.1136/jcp.46.10.908 8227406 1:STN:280:DyaK2c%2Fktlyitw%3D%3D
51. K Haruta S Kobayashi S Hirose A Horiai M Ohyanagi M Tanaka, et al. 1998 Monoclonal anti-cardiolipin antibodies from New Zealand Black x New Zealand White F1 mice react to thrombomodulin J Immunol 160 253 258 9551978 1:CAS:528:DyaK1cXhtFSqsA%3D%3D
52. JD Oosting KT Preissner RH Derksen PG de Groot 1993 Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro Br J Haematol 85 761 768 10.1111/j.1365-2141.1993.tb03220.x 7522520 1:CAS:528:DyaK2cXitFCrur0%3D
53. C Brisson G Archipoff M Hartmann D Hanau A Beretz J Freyssinet, et al. 1992 Antibodies to thrombomodulin induce receptor-mediated endocytosis in human saphenous vein endothelial cells Thromb Haemost 68 737 743 1337632 1:CAS:528:DyaK3sXht1altL8%3D